PAF (C16) (cas# 74389-68-7) is a blood platelet-activating factor, used to study human airway smooth muscle cell line.
C16-02:0 PC or 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine may be used as a substrate in enzymatic lipoprotein-associated phospholipase A2 (Lp-PLA2) activity assay. It may also be used to study its physicochemical properties and its interaction with peptides derived from the C-terminal domains of human apolipoprotein E.
ChEBI: A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.
C16-02:0 PC, also known as 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (C16 PAF) (acetyl PAF), is a platelet-activating factor (PAF). Acetyl PAF is present in the body and it contains ether-linked hexadecyl chain at the sn-1 position and an acetyl group at the sn-2 position.
Endogenous platelet-activating factor (PAF) and ligand for PAF receptors. Produced by inflammatory cells and a potent chemoattractant for polymorphonuclear neutrophils. Induces increased vascular permeability.
Platelet-activating factor (PAF) is a pro-inflammatory agent that exhibits variety of biological and pharmacological effects. It plays a major role in initiation and progression of atherosclerosis. PAF acts as a potential biomarker for coronary artery diseases. It yields LysoPAF (1-O-alkyl-2-hydroxy-sn-glycero-3-phosphocholine) on hydrolysis by platelet-activating factor-acetylhydrolase.
